Breaks Categories: Stock Spotlights

MondayApr 03, 2017 1:41 pm

NetworkNewsBreaks – Cancer Genetics, Inc. (NASDAQ: CGIX) Enters Strategic Partnership with Mendel.ai to Employ Artificial Intelligence in Precision Medicine

Cancer Genetics (NASDAQ: CGIX) (“CGI”) has entered into a strategic partnership with Mendel Health, an artificial intelligence company focused on using the Mendel.ai deep-learning engine to accelerate and constantly update clinical trial matching for patients. The companies will be collaborating to integrate Mendel.ai capabilities for clinicians, oncologists and pathologists, as well as cancer centers and hospitals with CGI’s disease-focused reports and testing results. The companies anticipate that initial, early-access partners will be using the system during the second quarter of 2017 with a more extensive rollout through the third and fourth quarters of this year. “Artificial intelligence has advanced and…

Continue Reading

MondayApr 03, 2017 12:22 pm

NetworkNewsBreaks – Interpace Diagnostics (NASDAQ: IDXG) Receives European Patent Approval For Core Technology of its ThyraMIR® microRNA Classifier

Interpace Diagnostics (NASDAQ: IDXG) shares are up 7% after the company said this morning that the European Patent Office granted it a patent for use of microRNAs for distinguishing benign from malignant thyroid neoplasms. This patent covers the underlying technology of the company's ThyraMIR® microRNA Classifier. Interpace intends to validate and enforce this Intellectual Property in select European countries going forward. "We are pleased to announce the approval of this patent by the European Patent Office as it provides a basis for introducing our first product to the European market as part of our international expansion plan. Importantly, this patent…

Continue Reading

FridayMar 31, 2017 12:56 pm

NetworkNewsBreaks – SeeThruEquity Issues Coverage Update, Raises PT to $1.50 on Generation Next Franchise Brands, Inc. (VEND)

SeeThruEquity recently issued an update on Generation Next Franchise Brands (OTCQB: VEND) and raised the price target on shares of the company’s stock to $1.50. The company recently entered into the frozen yogurt market through its three newly-formed subsidiaries: Reis and Irvy's Inc., 19 Degrees, Inc., and Generation Next Vending Robots, Inc. SeeThruEquity noted that the company appears to be gaining traction in the market and attributes the positive positioning to the company’s backlog of deferred revenue related to Froyo Robot bookings, franchise agreements, and an added revenue stream from royalties. The analyst also cited the company’s strengthened intellectual property…

Continue Reading

FridayMar 31, 2017 12:47 pm

NetworkNewsBreaks – ROTH Capital Partners To Host 4th Annual ROTH China Solar Tour in Conjunction with SNEC Power Expo in Shanghai

ROTH Capital Partners is hosting its 4th Annual China Solar Tour in Shanghai on April 18-21, 2017. The invitation-only event will be held in conjunction with the SNEC Power Expo, one of the largest annual solar conferences in the world. The event will be hosted by ROTH’s Philip Shen, senior research analyst, Cleantech, and will provide an opportunity for solar power industry executives, policymakers and key institutional investors to meet and exchange ideas about issues and trends in the solar and cleantech industry. “Innovation and growth continue to fuel the global solar industry, and China is a key centerpiece of…

Continue Reading

FridayMar 31, 2017 11:16 am

NetworkNewsBreaks – BioDelivery Sciences (NASDAQ: BDSI) Shares Higher on New Patents Protecting BELBUCA®, BUNAVAIL® and ONSOLIS®

BioDelivery Sciences (NASDAQ: BDSI) shares are up 7% after the company this morning said that it has received two new patents further strengthening BDSI's overall intellectual property position. The new patents protect all three of its FDA-approved products: BELBUCA® buccal film, BUNAVAIL® buccal film, and ONSOLIS®. One patent covers the composition of the BioErodible MucoAdhesive (BEMA®) drug delivery technology, which provides additional patent coverage for BELBUCA and BUNAVAIL to July 2027 and will be listed in the Orange Book. The second patent, also to be listed in the Orange Book, extends protection on ONSOLIS from January 2020 to July 2027.…

Continue Reading

ThursdayMar 30, 2017 1:15 pm

NetworkNewsBreaks – ProBility Media Corp. (PBYA) on Par with Skilled Trade Market; Develops Technical Training Brand For Over 60 Skilled Professions

The field for technical training is ripe, as the Bureau of Labor Statistics (BLS) forecasts continued growth for skilled trades. ProBility Media (OTCQB: PBYA) is a growing educational technology company developing the first full service training and career advancement brand for technical vocations and trades – right on par with the demand for career advancement for technical vocations and trades. “ProBility is the only company building the full spectrum of career training, advancement and compliance tools for tradesmen and technical experts in a wide variety of over 60 skilled professions. ProBility is executing a disruptive strategy of defragmenting the marketplace…

Continue Reading

ThursdayMar 30, 2017 10:33 am

NetworkNewsBreaks – MySize (NASDAQ: MYSZ) Trades Higher on Commercial Phase of KatzID Development

MySize (NASDAQ: MYSZ) shares are up 19% this morning after the company said it has completed the beta-pilot testing phase and has initiated the commercial phase of KatzID, a courier measurement application developed by MySize. KatzID will enable employees of Katz Corporation to easily and quickly measure the size of a parcel and calculate its exact shipping cost. The application also delivers barcode scanning, package pictures, location and more, which connect to Katz' ERP system to better manage their delivery processes. "Today marks a major milestone in the development of a very important product that is going to significantly improve…

Continue Reading

WednesdayMar 29, 2017 1:09 pm

NetworkNewsBreaks – Innocoll (NASDAQ: INNL) Receives FDA Meeting Minutes for XARACOLL® NDA; Shares Rally

Innocoll Holdings (NASDAQ: INNL) shares soared as much as 43% this morning – currently up 14% - after the company said it received formal Type A Meeting minutes from the United States Food and Drug Administration (FDA) relating to its New Drug Application (NDA) for XARACOLL. This clarifies the data that the company will need in order to address the questions raised in the Refusal to File (RTF) Letter the company received from the FDA in December 2016. During the Type A meeting, representatives of the FDA provided guidance which was confirmed in the formal FDA meeting minutes. The company…

Continue Reading

WednesdayMar 29, 2017 11:10 am

NetworkNewsBreaks – Players Network, Inc. (PNTV) Presenting at America First Investment Luncheon on March 31, 2017

Players Network’s (OTCQB: PNTV) CEO Mark Bradley and Director Brett H. Pojunis are set to present at the "America First Investment" financial luncheon hosted by ClubsCorp Business Network in Las Vegas on March 31, 2017, from 12:30-3:00 p.m. PDT. The diversified holding company was invited to present at the luncheon series that features select emerging companies who will present to attending investment bankers, institutional investors, and individual accredited investors. In addition to the presentation, both Bradley and Pojunis will be available for one-on-one meetings with investors. To register visit: https://goo.gl/gnkPRJ To view the full press release, visit: http://nnw.fm/Z3TrT About Players…

Continue Reading

TuesdayMar 28, 2017 10:58 am

NetworkNewsBreaks – Cempra, Inc. (NASDAQ: CEMP) Pulls Marketing Authorization Application for Solithromycin in Europe

Shares of Cempra (NASDAQ: CEMP) are down 5% mid-morning after the company said that it has withdrawn its marketing authorization application (MAA) seeking European Medicines Agency (EMA) approval of oral capsule and intravenous formulations of solithromycin for the treatment of community-acquired pneumonia in adults. The decision to withdraw was made based off of the Day 120 questions from the EMA, which caused the company to believe that additional data would be required. The company is now able to realign its strategy to provide additional data to both the EMA and U.S. Food and Drug Administration (FDA) to support potential approval.…

Continue Reading